SCHEMBL5468406

SCHEMBL5468406

O=C(Nc1cc(Cl)ccc1Cl)c1c[c]ccc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNMA1 Q12791 5/20 0.56
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ POLB P06746 1/20 0.49
▸ RAB9A P51151 2/20 0.48
▸ HDAC1 Q13547 1/20 0.48
▸ HDAC8 Q9BY41 1/20 0.48
▸ HDAC6 Q9UBN7 1/20 0.48
▸ P2RX1 P51575 5/20 0.48
▸ P2RX4 Q99571 2/20 0.48
▸ P2RX7 Q99572 2/20 0.48
▸ TMPRSS4 Q9NRS4 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.46
▸ TSHR P16473 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ TAS1R3 Q7RTX0 1/20 0.45
▸ TAS1R1 Q7RTX1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5457647 0.86 KCNMA1 (0.54) KCNMA1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5470386 0.83 TRPV1 (0.59) MEN1KMT2AHDAC1HDAC8TMPRSS4
SCHEMBL5460243 0.83 KCNMA1 (0.50) KCNMA1MEN1KMT2APOLBRAB9A
SCHEMBL5460406 0.83 KCNMA1 (0.62) KCNMA1MEN1KMT2APOLBHDAC1
SCHEMBL5468325 0.82 RORC (0.57) KCNMA1MEN1KMT2APOLBRAB9A
SCHEMBL330387 0.82 KCNMA1 (0.81) KCNMA1MEN1KMT2APOLBRAB9A
SCHEMBL5463888 0.79 PTGS1 (0.56) MEN1KMT2APOLBRAB9AHDAC1
SCHEMBL5462668 0.76 TAS1R3 (0.52) KCNMA1MEN1KMT2APOLBP2RX1
SCHEMBL14363353 0.76 KCNMA1 (0.66) KCNMA1MEN1KMT2APOLBRAB9A
SCHEMBL5464092 0.75 TOP1 (0.46) MEN1KMT2AP2RX1P2RX4P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US claimed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP claimed
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 KCNMA1 1503/4885MEN1 2892/4885KMT2A 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback